People look at the cost structure and there was a note coming out about the cost structure of cell therapy ... patients. And so what that would do is allow more patients to benefit from CASGEVY ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

SG: We look to do business development in each of our ... it’s about bringing products to patients. Like our competition we put a concerted effort into improving our alliance management capability.

However, Casgevy's potential ... in this field. Look for Regeneron to fill the gap that the old formulation of Eylea will leave through innovation and its existing medicines like Dupixent, HD ...

Feel like you ... see that the patient is approaching his present circumstances as an adult ... that he has learned to look at his behavior and understand its meaning, and can do things to change ...

With the success of the monotherapy checkpoint inhibitors, researchers are starting to look ... in the patient. Would you say that immunotherapy has lived up to its expectations or do they still ...

which may look like progress updates, insight into your child’s behavior, and strategies for you to utilize at home. There are many things that parents can do to best support the play therapy ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Stocks started rising as the day unfolded with Fed Chair Jerome Powell reinforcing that interest rates remain in a "good ...

UPMC said that it will soon require all patients, visitors, support persons and staff to wear masks in its patient care areas ...